Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 11:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 62 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Water Concentration 3 Clear all
Completed Not applicable Interventional Accepts healthy volunteers

A Single-Group Study to Examine the Efficacy of a Melatonin Lotion With Magnesium to Improve Sleep Quality and Quantity

NCT06146712
View directory record Official record
Conditions
Sleep
Interventions
Asutra's 'Dream the night away' nighttime lotion
Other
Lead sponsor
Asutra
Industry
Eligibility
18 Years to 59 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Nov 27, 2023 · Synced Oct 23, 2026, 11:35 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Granulation Tissue Treatment: Silver Nitrate vs Kenalog vs Washcloth Abrasion

NCT02519738
View directory record Official record
Conditions
Other Abnormal Granulation Tissue Nos
Interventions
Silver Nitrate, Kenalog (Triamcinolone), Washcloth Abrasion
Drug · Other
Lead sponsor
University of Michigan
Other
Eligibility
Up to 17 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 25, 2022 · Synced Oct 23, 2026, 11:35 AM EDT
Completed Phase 3 Interventional Results available

Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-2)

NCT04249076
View directory record Official record
Conditions
Cataract
Interventions
Clobetasol Propionate, Vehicle
Drug
Lead sponsor
Salvat
Industry
Eligibility
18 Years and older
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
18
States / cities
Sun City, Arizona • Hemet, California • Inglewood, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2022 · Synced Oct 23, 2026, 11:35 AM EDT
Completed Phase 4 Interventional Results available

Effect of Valproic Acid Concentration on Photic Response

NCT00609245
View directory record Official record
Conditions
Photosensitive Epilepsy
Interventions
Valproic Acid, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
15 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Chesterfield, Missouri • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 23, 2026, 11:35 AM EDT
Terminated Phase 1 Interventional

Safety, Tolerability, PK, Dosimetry, MTD and Preliminary Efficacy of Intra-lesionally Injected AvidinOX, Followed by IV Escalating Doses of [177Lu]DOTA-biotin in Pts With Injectable Solid Tumors or Lymphomas

NCT03188328
View directory record Official record
Conditions
Inoperable Solid Tumors or Lymphomas
Interventions
AvidinOX, 177Lu-ST2210
Drug
Lead sponsor
Alfasigma S.p.A.
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 5, 2019 · Synced Oct 23, 2026, 11:35 AM EDT
Completed Not applicable Interventional

The Effect of Prophylactic Swallowing Exercises on Head and Neck Cancer Patients

NCT01349309
View directory record Official record
Conditions
Dysphagia
Interventions
Swallowing Exercise Group
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 4, 2015 · Synced Oct 23, 2026, 11:35 AM EDT
Completed Phase 3 Interventional Results available

Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)

NCT02367040
View directory record Official record
Conditions
Lymphoma,Non-Hodgkin
Interventions
Copanlisib (Aliqopa, BAY80-6946), Placebo, Rituximab
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
16
States / cities
West Covina, California • Ashland, Kentucky • Louisville, Kentucky + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 23, 2026, 11:35 AM EDT
Active, not recruiting Not applicable Interventional

Effect of Tao Calligraphy Meditation and Energized Water on Depression

NCT06934330
View directory record Official record
Conditions
Unipolar Depression
Interventions
Mindfulness practice with Tao Art (Calligraphy and Song Greatest Love), Drinking Energized water
Behavioral · Other
Lead sponsor
Sha Research Foundation
Other
Eligibility
19 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Kahului, Hawaii
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 23, 2026, 11:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of the Safety of QRH-882260 Heptapeptide

NCT02574858
View directory record Official record
Conditions
Healthy Adults
Interventions
QRH-882260
Drug
Lead sponsor
University of Michigan
Other
Eligibility
25 Years to 100 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 2, 2018 · Synced Oct 23, 2026, 11:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Sanaria PfSPZ Challenge With Pyrimethamine Chemoprophylaxis (PfSPZ-CVac Approach): Phase 1 Trial to Determine Safety and Protective Efficacy of Sanaria PfSPZ Challenge With Concurrent Pyrimethamine Treatment That Inhibits Development of Asexual B...

NCT02511054
View directory record Official record
Conditions
Malaria
Interventions
Chloroquine (CQ), Pyrimethamine (PYR), Sanaria PfSPZ Challenge (NF54)
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 23, 2026, 11:35 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Sexual Absorption of Vaginal Progesterone

NCT01959464
View directory record Official record
Conditions
Infertility, Pregnancy
Interventions
Crinone vaginal progesterone gel, Placebo vaginal gel
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 22, 2022 · Synced Oct 23, 2026, 11:35 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Water Content in E-Liquids

NCT05257109
View directory record Official record
Conditions
Nicotine E-Cigarette Use
Interventions
Water Concentration 1, Water Concentration 2, Water Concentration 3, Water Concentration 4
Other
Lead sponsor
Yale University
Other
Eligibility
21 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Oct 23, 2026, 11:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Mechanisms of Cerebrovascular Control

NCT02936687
View directory record Official record
Conditions
Metabolic Syndrome X
Interventions
NOS Inhibition, ET-1 Inhibition, NOS Inhibition Placebo, 3 Tesla MRI, Intravenous Catheter, Oral Glucose Tolerance Test, ET-1 Inhibition Placebo
Drug · Device · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 45 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 18, 2021 · Synced Oct 23, 2026, 11:35 AM EDT
Completed Phase 1 Interventional Results available

Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors

NCT03154294
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
paclitaxel, TAK-228, TAK-117
Drug
Lead sponsor
Avera McKennan Hospital & University Health Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Jul 26, 2024 · Synced Oct 23, 2026, 11:35 AM EDT
Completed Phase 1 Interventional

Effect of Sublingual Formulation of Dexmedetomidine HCl (BXCL501) - Alcohol Interaction Study

NCT04827056
View directory record Official record
Conditions
Alcohol Use Disorder (AUD), Post Traumatic Stress Disorder (PTSD)
Interventions
Placebo, Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg, Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 80µg, Ethanol Infusion, PTSD Reactivity Condition, Alcohol Cue Reactivity
Drug · Procedure · Behavioral
Lead sponsor
Pharmacotherapies for Alcohol and Substance Use Disorders Alliance
Other
Eligibility
21 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Oct 23, 2026, 11:35 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)

NCT03619850
View directory record Official record
Conditions
Chronic Kidney Disease; Iron Deficiency Anemia
Interventions
Ferumoxytol, Iron sucrose
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
2 Years to 17 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
8
States / cities
Hollywood, Florida • Detroit, Michigan • Kansas City, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 23, 2026, 11:35 AM EDT
Recruiting Phase 4 Interventional

Preoperative BOTOX® Injection for Large Ventral Hernia Repair

NCT07220382
View directory record Official record
Conditions
Hernia Abdominal Wall, Botox Injection, Hernia Incisional Ventral, Hernia Repair With Compartment Syndrome, Hernia Surgery, Hernia, Hernia Incisional
Interventions
OnabotulinumtoxinA Injection, Saline (placebo) Injection, OnabotulinumtoxinA, 0.9 % Normal Saline, Open Ventral Hernia Repair
Procedure · Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 23, 2026, 11:35 AM EDT
Active, not recruiting Phase 2 Interventional

FDOPA PET and Nutritional Support in Parkinson's Disease

NCT04459052
View directory record Official record
Conditions
Parkinson Disease, Idiopathic Parkinson Disease
Interventions
N acetyl cysteine, [F-18] Fluorodopa Positron Emission Tomography
Dietary Supplement · Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
30 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Oct 23, 2026, 11:35 AM EDT
Completed Not applicable Interventional

The Effects of Virtual Zumba® in Individuals With Developmental Disabilities

NCT05198232
View directory record Official record
Conditions
Developmental Disability, Autism Spectrum Disorder, Down Syndrome, Cerebral Palsy
Interventions
Zumba High Tempo, Zumba Low Tempo
Behavioral
Lead sponsor
Auburn University
Other
Eligibility
18 Years to 75 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Auburn, Alabama
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Oct 23, 2026, 11:35 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Examining the Differential Effects of Traditional Float-REST and Dry Float on Subjective and Objective Health Outcomes

NCT04628910
View directory record Official record
Conditions
Sleep Quality
Interventions
Simulated Flotation Therapy, Traditional Float-REST Therapy
Other
Lead sponsor
West Virginia University
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Oct 23, 2026, 11:35 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Safety and Efficacy of KH-1 for Stimulating Autophagy in Non-diabetic Adults With Elevated Blood Glucose Concentration

NCT06445569
View directory record Official record
Conditions
PreDiabetes, Aging
Interventions
KH-1, Placebo
Dietary Supplement · Other
Lead sponsor
Kalin Health, LLC
Industry
Eligibility
50 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Oct 23, 2026, 11:35 AM EDT
Completed Phase 4 Interventional

TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study

NCT05002998
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
Teprotumumab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
7
States / cities
Beverly Hills, California • Los Angeles, California • Palo Alto, California + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 23, 2026, 11:35 AM EDT
Recruiting Not applicable Interventional

Safety and Efficacy of Head-lice Treatments Elimax Green Lotion and Walgreens Lice Killing Shampoo

NCT07191457
View directory record Official record
Conditions
Head Lice
Interventions
Elimax Green Lotion with Emogreen, Walgreens Lice Killing Shampoo
Device · Drug
Lead sponsor
Oystershell NV
Industry
Eligibility
6 Months and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Enid, Oklahoma
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Oct 23, 2026, 11:35 AM EDT
Completed Phase 2 Interventional Results available

High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma

NCT00349778
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Cyclophosphamide, Etoposide, Melphalan, Carmustine, Filgrastim
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Oct 23, 2026, 11:35 AM EDT